Related Experiment Video
Updated: Jun 21, 2026

An Emerging Target Paradigm to Evoke Fast Visuomotor Responses on Human Upper Limb Muscles
Published on: August 25, 2020
Lessons learned from the ONTARGET and TRANSCEND trials
1Ralph H. Johnson VA Medical Center, Medical University of South Carolina, Charleston, SC 29401, USA. Jan.Basile@med.va.gov
Insights
Blocking the renin-angiotensin-aldosterone system (RAAS) is crucial for managing hypertension and cardiovascular disease (CVD). Key trials like ONTARGET and TRANSCEND demonstrate the efficacy of RAAS inhibitors in high-risk patients.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Cardiovascular disease (CVD) is a leading cause of death in the US.
- The renin-angiotensin-aldosterone system (RAAS) plays a significant role in blood pressure regulation and CVD.
- Targeting the RAAS is a key strategy for treating hypertension and cardiovascular conditions.
Purpose of the Study:
- To review the outcomes of the ONTARGET and TRANSCEND trials.
- To discuss the role of RAAS inhibition in managing high-risk cardiovascular patients.
- To identify clinical practice issues regarding RAAS-targeting therapies.
Main Methods:
- Analysis of data from the Ongoing Telmisartan Alone and in Combination with Ramipril Global endpoint Trial (ONTARGET).
- Review of findings from the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects with Cardiovascular Disease (TRANSCEND).
Main Results:
- Both trials demonstrated the effectiveness of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in reducing CVD.
- Specific outcomes related to telmisartan in combination therapy and in ACE-intolerant patients were highlighted.
Conclusions:
- RAAS inhibition is a vital therapeutic approach for patients with hypertension and existing CVD.
- Clinical decisions on selecting RAAS-targeting therapies require careful consideration of trial data and patient profiles.
Abstract:
Cardiovascular disease (CVD) accounts for one of every three deaths in the United States. In recent years, a greater understanding of the renin-angiotensin-aldosterone system's (RAAS) contribution to CVD, particularly in the area of blood pressure regulation, has emerged. Thus, interrupting or blocking the RAAS has become a key component in the treatment of hypertension and other cardiovascular conditions. The role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in reducing CVD in high-risk populations has been demonstrated by two recently completed major trials: the Ongoing Telmisartan Alone and in Combination with Ramipril Global endpoint Trial (ONTARGET) and the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects with Cardiovascular Disease (TRANSCEND). This article describes these key studies and their outcomes and identifies critical issues that they raise for clinical practice in terms of choosing the most effective therapy for patients with existing CVD.
Related Concept Videos
Hindsight Biases
Robbers Cave
The Stanford Prison Experiment
Purposive Learning
Modeling in Therapy
Participant Modeling
Participant modeling involves therapists demonstrating calm and effective behaviors in situations...
Improving Translational Accuracy
